SNCA Antibodies

SNCA antibodies are designed to specifically target alpha-synuclein (SNCA), a neuronal protein that plays a crucial role in synaptic function and neurotransmitter release. SNCA is predominantly expressed in the brain, where it contributes to synaptic vesicle regulation. However, abnormal aggregation of SNCA is a key pathological feature of neurodegenerative disorders, including Parkinson’s disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB).

Content

Alpha-synuclein (SNCA) is a small, soluble protein primarily located at presynaptic terminals in neurons. It is involved in synaptic vesicle trafficking and regulation of neurotransmitter release. In its normal state, SNCA exists as an unstructured monomer, but under pathological conditions, it can misfold and aggregate into insoluble fibrils, forming Lewy bodies—a hallmark of Parkinson's disease and related disorders.

Application

SNCA antibodies are widely applied in various research and diagnostic techniques, including:

Western Blotting (WB): For the detection and quantification of alpha-synuclein protein in cell lysates and tissue extracts. This helps in studying the expression patterns and post-translational modifications of SNCA, such as phosphorylation and ubiquitination.
Immunohistochemistry (IHC): Used to visualize SNCA expression and aggregation in tissue sections, particularly in brain samples. IHC with SNCA antibodies is essential for identifying Lewy bodies and Lewy neurites in samples from patients with PD, MSA, and DLB.
Enzyme-Linked Immunosorbent Assay (ELISA): Employed to quantify SNCA protein levels in various biological samples, including cerebrospinal fluid (CSF) and serum. ELISA is useful for biomarker research aimed at developing diagnostic tests for synucleinopathies.
Immunoprecipitation (IP): Used to isolate SNCA from complex mixtures, facilitating studies on protein-protein interactions and the investigation of its aggregation behavior.

SNCA antibodies are essential for advancing the understanding of neurodegenerative diseases characterized by synucleinopathies. They aid in investigating the mechanisms underlying alpha-synuclein aggregation, its role in disease progression, and the development of potential therapeutic strategies that target abnormal SNCA processing and aggregation.